Literature DB >> 24442597

Suboptimal use of imaging in the new (National Comprehensive Cancer Network) International Prognostic Index for diffuse large B-cell lymphoma.

Hugo J A Adams1, Thomas C Kwee.   

Abstract

Mesh：

Year:  2014        PMID： 24442597     DOI： 10.1007/s00259-013-2669-3

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  8 in total

Review 1.  Improving outcomes for patients with diffuse large B-cell lymphoma.

Authors:  Christopher R Flowers; Rajni Sinha; Julie M Vose
Journal:  CA Cancer J Clin       Date:  2010-10-28       Impact factor: 508.702

2.  Direct comparison of FDG PET and CT findings in patients with lymphoma: initial experience.

Authors:  Mitsuaki Tatsumi; Christian Cohade; Yuji Nakamoto; Elliot K Fishman; Richard L Wahl
Journal:  Radiology       Date:  2005-12       Impact factor: 11.105

3.  Baseline total lesion glycolysis measured with (18)F-FDG PET/CT as a predictor of progression-free survival in diffuse large B-cell lymphoma: a pilot study.

Authors:  Shadi A Esfahani; Pedram Heidari; Elkan F Halpern; Ephraim P Hochberg; Edwin L Palmer; Umar Mahmood
Journal:  Am J Nucl Med Mol Imaging       Date:  2013-04-09

4.  Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma.

Authors:  Malik E Juweid; Sigrid Stroobants; Otto S Hoekstra; Felix M Mottaghy; Markus Dietlein; Ali Guermazi; Gregory A Wiseman; Lale Kostakoglu; Klemens Scheidhauer; Andreas Buck; Ralph Naumann; Karoline Spaepen; Rodney J Hicks; Wolfgang A Weber; Sven N Reske; Markus Schwaiger; Lawrence H Schwartz; Josee M Zijlstra; Barry A Siegel; Bruce D Cheson
Journal:  J Clin Oncol       Date:  2007-01-22       Impact factor: 44.544

5.  The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP.

Authors:  Laurie H Sehn; Brian Berry; Mukesh Chhanabhai; Catherine Fitzgerald; Karamjit Gill; Paul Hoskins; Richard Klasa; Kerry J Savage; Tamara Shenkier; Judy Sutherland; Randy D Gascoyne; Joseph M Connors
Journal:  Blood       Date:  2006-11-14       Impact factor: 22.113

6.  Total lesion glycolysis in positron emission tomography is a better predictor of outcome than the International Prognostic Index for patients with diffuse large B cell lymphoma.

Authors:  Tae Min Kim; Jin Chul Paeng; In Kook Chun; Bhumsuk Keam; Yoon Kyung Jeon; Se-Hoon Lee; Dong-Wan Kim; Dong Soo Lee; Chul Woo Kim; June-Key Chung; Il Han Kim; Dae Seog Heo
Journal:  Cancer       Date:  2012-12-04       Impact factor: 6.860

7.  A predictive model for aggressive non-Hodgkin's lymphoma.

Authors: 
Journal:  N Engl J Med       Date:  1993-09-30       Impact factor: 91.245

8.  An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era.

Authors:  Zheng Zhou; Laurie H Sehn; Alfred W Rademaker; Leo I Gordon; Ann S Lacasce; Allison Crosby-Thompson; Ann Vanderplas; Andrew D Zelenetz; Gregory A Abel; Maria A Rodriguez; Auayporn Nademanee; Mark S Kaminski; Myron S Czuczman; Michael Millenson; Joyce Niland; Randy D Gascoyne; Joseph M Connors; Jonathan W Friedberg; Jane N Winter
Journal:  Blood       Date:  2013-11-21       Impact factor: 22.113
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.